Literature DB >> 16787176

Antimicrobial peptides in COPD--basic biology and therapeutic applications.

Robert Bals1, Pieter S Hiemstra.   

Abstract

A large number of studies have implicated activation of innate immune mechanisms in the pathogenesis of chronic obstructive pulmonary disease (COPD). Accumulation of inflammatory cells, chemokines and pro-inflammatory cytokines is a hallmark of activation of these mechanisms, but only a few studies have focussed on antimicrobial peptides in COPD. These peptides are a central component of innate immunity, and airway epithelial cells and neutrophils in the lung are the main cellular sources. In addition to their direct antimicrobial action, antimicrobial peptides have been shown to display a variety of activities that may implicate them in the pathogenesis of COPD. This is based on the observation that they not only contribute to defense against respiratory pathogens that have been associated with COPD, but may also contribute to the influx of inflammatory cells, activation of adaptive immunity and epithelial remodeling. The aim of this review is to provide an update on the basic biology of antimicrobial peptides in the lung, with a focus on their putative role in COPD. In addition, the implication of this knowledge for future treatment of COPD is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16787176     DOI: 10.2174/138945006777435227

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  6 in total

Review 1.  Multifunctional antimicrobial peptides: therapeutic targets in several human diseases.

Authors:  Mohamed Zaiou
Journal:  J Mol Med (Berl)       Date:  2007-01-10       Impact factor: 4.599

2.  S100A7/psoriasin expression in the human lung: unchanged in patients with COPD, but upregulated upon positive S. aureus detection.

Authors:  Ellen Andresen; Christoph Lange; Daniela Strodthoff; Torsten Goldmann; Nicole Fischer; Hany Sahly; Detlev Branscheid; Holger Heine
Journal:  BMC Pulm Med       Date:  2011-02-15       Impact factor: 3.317

Review 3.  Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease.

Authors:  Tapan Dey; Jatin Kalita; Sinéad Weldon; Clifford C Taggart
Journal:  J Clin Med       Date:  2018-08-28       Impact factor: 4.241

4.  Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease.

Authors:  Pelin Uysal; Gonul Simsek; Sinem Durmus; Volkan Sozer; Hulya Aksan; Sibel Yurt; Caglar Cuhadaroglu; Filiz Kosar; Remise Gelisgen; Hafize Uzun
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-01-25

Review 5.  Future therapeutic treatment of COPD: struggle between oxidants and cytokines.

Authors:  Willem I de Boer; Hongwei Yao; Irfan Rahman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

6.  Osteopontin That Is Elevated in the Airways during COPD Impairs the Antibacterial Activity of Common Innate Antibiotics.

Authors:  Anele Gela; Ravi K V Bhongir; Michiko Mori; Paul Keenan; Matthias Mörgelin; Jonas S Erjefält; Heiko Herwald; Arne Egesten; Gopinath Kasetty
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.